Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure
- M M Winter1,
- B J Bouma1,
- M Groenink1,2,
- T C Konings3,
- J G P Tijssen1,
- D J van Veldhuisen4,
- B J M Mulder1,5
- 1Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
- 2Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
- 3Department of Cardiology, VU Medical Center, Amsterdam, The Netherlands
- 4Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
- 5Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
- Professor Barbara J M Mulder, Academic Medical Center, Department of Cardiology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; b.j.mulder{at}amc.uva.nl
- Accepted 16 September 2008
- Published Online First 25 November 2008
Abstract
The number of adult patients with a systemic right ventricle (RV) is steadily increasing. Survival is relatively good in these patients, but deterioration of the systemic RV seems inevitable. Although therapeutic options for patients with LV failure are well established, their role in patients with systemic RV failure is often undefined. To appreciate the potency of LV failure therapy in patients with a systemic RV, insight into pathophysiology of systemic RV failure and into recent developments in therapeutic research are indispensible. This review provides these insights, and will facilitate and ameliorate therapeutic decision making in patients with a systemic RV.
Footnotes
-
Funding: This study was supported by an unrestricted educational grant from Novartis Pharma BV.
-
Competing interests: None.









